ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.497,94
-0,09%
S&P 500
5.277,51
0,80%
Dow Jones
38.686,32
1,51%
Euro vs US Dollar
1,08565
0,00%
Bitcoin
67.729,70
0,01%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. GlycoMimetics Inc (GLYC)

  7. GlycoMimetics Inc (GLYC) News

GLYC

GlycoMimetics (GLYC)

GlycoMimetics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:GLYC
DatumZeitQuelleÜberschriftSymbolFirma
29/05/202422h01Business WireGlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024NASDAQ:GLYCGlycoMimetics Inc
09/05/202422h31Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:GLYCGlycoMimetics Inc
06/05/202422h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GLYCGlycoMimetics Inc
06/05/202412h00Business WireGlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)NASDAQ:GLYCGlycoMimetics Inc
25/04/202413h00Business WireGlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024NASDAQ:GLYCGlycoMimetics Inc
27/03/202412h00Business WireGlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023NASDAQ:GLYCGlycoMimetics Inc
13/03/202412h00Business WireGlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024NASDAQ:GLYCGlycoMimetics Inc
01/03/202415h16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GLYCGlycoMimetics Inc
26/02/202413h00Business WireGlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care ConferenceNASDAQ:GLYCGlycoMimetics Inc
12/02/202413h00Business WireGlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:GLYCGlycoMimetics Inc
17/01/202422h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GLYCGlycoMimetics Inc
17/01/202422h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GLYCGlycoMimetics Inc
17/01/202422h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GLYCGlycoMimetics Inc
17/01/202422h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GLYCGlycoMimetics Inc
17/01/202422h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GLYCGlycoMimetics Inc
04/01/202413h00Business WireGlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687NASDAQ:GLYCGlycoMimetics Inc
03/01/202413h00GlobeNewswire Inc.Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid LeukemiaNASDAQ:GLYCGlycoMimetics Inc
02/01/202422h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GLYCGlycoMimetics Inc
02/01/202422h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GLYCGlycoMimetics Inc
02/01/202422h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GLYCGlycoMimetics Inc
02/01/202422h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GLYCGlycoMimetics Inc
10/12/202318h00Business WireGlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid LeukemiaNASDAQ:GLYCGlycoMimetics Inc
09/11/202313h00Business WireGlycoMimetics to Participate in Upcoming Jefferies London Healthcare ConferenceNASDAQ:GLYCGlycoMimetics Inc
03/11/202313h35Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GLYCGlycoMimetics Inc
03/11/202313h31Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:GLYCGlycoMimetics Inc
03/11/202312h00Business WireGlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023NASDAQ:GLYCGlycoMimetics Inc
23/10/202314h30PR Newswire (US)Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory BoardNASDAQ:GLYCGlycoMimetics Inc
20/10/202313h00Business WireGlycoMimetics to Report Third Quarter 2023 Financial Results on November 3, 2023NASDAQ:GLYCGlycoMimetics Inc
03/10/202322h15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GLYCGlycoMimetics Inc
03/10/202322h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GLYCGlycoMimetics Inc
 Showing the most relevant articles for your search:NASDAQ:GLYC

Kürzlich von Ihnen besucht

USOTC
BNPQY
BNP Paribas (QX)
USOTC
RHHBY
Roche (QX)
NASDAQ
TSLA
Tesla
TG
ALV
Allianz
NASDAQ
MSFT
Microsoft
USOTC
DTEGY
Deutsche Telekom (QX)
USOTC
BASFY
BASF (QX)
USOTC
ADDYY
Adidas (QX)
TG
D7G
Nel ASA
NASDAQ
GOOGL
Alphabet
CCOM
US100
US Tech 100
TG
CBK
Commerzbank
CCOM
US500
US 500
DBI
SDXP
SDAX
AMEX
XLE
Energy Select Sector SPDR
NYSE
MRK
Merck
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten